In HER2-positive breast cancer and TNBC, the rates of brain metastases are 11–49% and 26–46%, respectively, while in patients with metastatic luminal A and B cancer, the risk of brain metastases are 8–15% and 11%, respectively [2,3,4,5,6,7,8]. This evidence concerns the gene ERBB2 and breast carcinoma.